Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENWORTH FINANCIAL INCGNW · Entity 4085 | Director | May 20, 2026 | May 21, 2026 |
| Viatris IncVTRS · Entity 3277 | Director | March 06, 2026 | March 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENWORTH FINANCIAL INC
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,728.537 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 31,547 · Balance 163,728.537 F1: Reflects award of restricted stock units (RSUs) in payment of a portion of the reporting person's annual retainer fee. The RSUs vest on the one-year anniversary of the grant date, and convert to shares of Common Stock upon vesting (unless the reporting person elected to defer receipt of the shares until termination of service as a director or to a future specified year). F2: Reflects the twenty-day average trading price per share of Common Stock, which was used to determine the number of RSUs granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects award of restricted stock units (RSUs) in payment of a portion of the reporting person's annual retainer fee. The RSUs vest on the one-year anniversary of the grant date, and convert to shares of Common Stock upon vesting (unless the reporting person elected to defer receipt of the shares until termination of service as a director or to a future specified year).
F2: Reflects the twenty-day average trading price per share of Common Stock, which was used to determine the number of RSUs granted.
Viatris Inc
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,048 |
Ending reported balance
After 2026-03-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-06 · Exercise / conversion · Acquired 23,660 · Balance 144,873 Row 2 · 2026-03-06 · Exercise / conversion · Acquired 1,175 · Balance 146,048 F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-06 · Exercise / conversion · Disposed 23,660 · Balance 0 F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,890 |
Reported balance
After 2026-03-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-06 · Grant · Acquired 15,890 · Balance 15,890 F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-06 · Exercise / conversion · Disposed 1,174.4921 · Balance 0 F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 74,000 |
Reported balance
Holding disclosure · report date 2026-03-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 74,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Fractional shares have been rounded up in connection with the settlement described in footnote 3 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F2: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026.
F3: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.
F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mylan II B.V.
Report date November 16, 2020 · Filed November 19, 2020
Section 16 reporting ended · disclosed 2020-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 39,131 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 74,000 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $31.63 · Expires 2023-05-28 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 6,623 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F4: These options vested on May 28, 2014. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.72 · Expires 2024-04-11 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 2,974 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5: These options vested on April 11, 2015. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $50.66 · Expires 2025-11-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 2,603 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6: These options vested on May 1, 2016. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $46.27 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 2,788 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7: These options vested on February 17, 2017. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $45.18 · Expires 2027-03-03 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 2,928 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8: These options vested on March 3, 2018. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $40.97 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 2,984 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9: These options vested on March 2, 2019. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Disposition to issuer · Disposed 4,352 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F10: These options vested on March 2, 2020. |
| Non-Employee Director Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-16 · Disposition to issuer · Disposed 6,151 · Balance 0 F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F11: These options will vest on March 2, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-11-16 · Disposition to issuer · Disposed 9,440 · Balance 0 F12: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F13: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
F2: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
F3: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.
F4: These options vested on May 28, 2014.
F5: These options vested on April 11, 2015.
F6: These options vested on May 1, 2016.
F7: These options vested on February 17, 2017.
F8: These options vested on March 3, 2018.
F9: These options vested on March 2, 2019.
F10: These options vested on March 2, 2020.
F11: These options will vest on March 2, 2021.
F12: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination.
F13: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021.
Virgin Orbit Holdings, Inc.
Report date December 29, 2021 · Filed January 04, 2022
Section 16 reporting ended · disclosed 2022-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
After 2021-12-29 transaction · row 1
1 source rowRow 1 · 2021-12-29 · Grant · Acquired 125,000 · Balance 125,000 F1: Reflects Issuer's common stock acquired from the Issuer pursuant to a Subscription Agreement in connection with the business combination of NextGen Acquisition Corp. II (the former name of the Issuer) and Virgin Orbit Holdings, Inc. (formerly known as Virgin Orbit) (such business combination, the "Business Combination"), which closed on December 29, 2021. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Issuer's common stock acquired from the Issuer pursuant to a Subscription Agreement in connection with the business combination of NextGen Acquisition Corp. II (the former name of the Issuer) and Virgin Orbit Holdings, Inc. (formerly known as Virgin Orbit) (such business combination, the "Business Combination"), which closed on December 29, 2021. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 6,151 | Not disclosed Strike: $17.48 | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 10 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,151 Underlying: Common Stock · 6,151 shares Expires 2030-03-02 F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F11 · derivative.exercise_date: These options will vest on March 2, 2021. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 4,352 | Not disclosed Strike: $27.45 | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 9 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 Underlying: Common Stock · 4,352 shares Expires 2029-03-01 F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F10 · derivative.exercise_date: These options vested on March 2, 2020. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,984 | Not disclosed Strike: $40.97 | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 8 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 Underlying: Common Stock · 2,984 shares Expires 2028-03-02 F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F9 · derivative.exercise_date: These options vested on March 2, 2019. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,928 | Not disclosed Strike: $45.18 | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 7 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928 Underlying: Common Stock · 2,928 shares Expires 2027-03-03 F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F8 · derivative.exercise_date: These options vested on March 3, 2018. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,788 | Not disclosed Strike: $46.27 | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 6 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,788 Underlying: Common Stock · 2,788 shares Expires 2026-02-17 F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F7 · derivative.exercise_date: These options vested on February 17, 2017. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,603 | Not disclosed Strike: $50.66 | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 5 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,603 Underlying: Common Stock · 2,603 shares Expires 2025-11-17 F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F6 · derivative.exercise_date: These options vested on May 1, 2016. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 2,974 | Not disclosed Strike: $45.72 | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 4 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974 Underlying: Common Stock · 2,974 shares Expires 2024-04-11 F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F5 · derivative.exercise_date: These options vested on April 11, 2015. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantNon-Employee Director Stock Option - Right to Buy · Derivative | 6,623 | Not disclosed Strike: $31.63 | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · derivative · entry 3 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,623 Underlying: Common Stock · 6,623 shares Expires 2023-05-28 F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination. F4 · derivative.exercise_date: These options vested on May 28, 2014. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantCommon Stock | 74,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · nonDerivative · entry 2 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 74,000 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | Viatris Inc VTRS · Entity 3277 | GrantCommon Stock | 39,131 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031573 · doc4.xml · nonDerivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,131 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerRestricted Stock Units · Derivative | 9,440 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 11 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,440 shares Expires not disclosed F12 · security: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F12 · price: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F13 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. F13 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 6,151 | Not disclosed Strike: $17.48 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 10 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,151 shares Expires 2030-03-02 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F11 · derivative.exercise_date: These options will vest on March 2, 2021. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 4,352 | Not disclosed Strike: $27.45 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 9 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,352 shares Expires 2029-03-01 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F10 · derivative.exercise_date: These options vested on March 2, 2020. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,984 | Not disclosed Strike: $40.97 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 8 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,984 shares Expires 2028-03-02 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9 · derivative.exercise_date: These options vested on March 2, 2019. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,928 | Not disclosed Strike: $45.18 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 7 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,928 shares Expires 2027-03-03 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8 · derivative.exercise_date: These options vested on March 3, 2018. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,788 | Not disclosed Strike: $46.27 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 6 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,788 shares Expires 2026-02-17 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7 · derivative.exercise_date: These options vested on February 17, 2017. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,603 | Not disclosed Strike: $50.66 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 5 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,603 shares Expires 2025-11-17 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6 · derivative.exercise_date: These options vested on May 1, 2016. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 2,974 | Not disclosed Strike: $45.72 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 4 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,974 shares Expires 2024-04-11 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5 · derivative.exercise_date: These options vested on April 11, 2015. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerNon-Employee Director Stock Option - Right to Buy · Derivative | 6,623 | Not disclosed Strike: $31.63 | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · derivative · entry 3 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,623 shares Expires 2023-05-28 F3 · security: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F3 · price: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F4 · derivative.exercise_date: These options vested on May 28, 2014. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerOrdinary Shares | 74,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · nonDerivative · entry 2 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · price: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:19 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerOrdinary Shares | 39,131 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031507 · doc4.xml · nonDerivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2 · price: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:16 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 9,058.205 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052676 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,837.607 Underlying: Class A Common Stock · 9,058.205 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $3.3585 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 21:20 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 12,093.34 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-039811 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,779.402 Underlying: Class A Common Stock · 12,093.34 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $2.9355 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 20:41 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 8,848.455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-022138 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,686.062 Underlying: Class A Common Stock · 8,848.455 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $4.0120 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 23:30 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 6,011 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007014 · doc4.xml · derivative · entry 5 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,011 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2020. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2020. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 23:30 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 9,440 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007014 · doc4.xml · derivative · entry 4 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,440 Underlying: Ordinary Shares · 9,440 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2021. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2021. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 23:30 UTC | Mylan II B.V. MYL · Entity 16217 | GrantNon-Employee Director Stock Option-Right to Buy · Derivative | 6,151 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0000899243-20-007014 · doc4.xml · derivative · entry 3 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,151 Underlying: Ordinary Shares · 6,151 shares Expires 2030-03-02 F1 · derivative.exercise_date: These options will vest in full on March 2, 2021 and expire on March 2, 2030. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 23:30 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 6,011 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007014 · doc4.xml · nonDerivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:17 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 2,079.699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-000282 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,837.607 Underlying: Class A Common Stock · 2,079.699 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $4.3305 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 20:17 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 8,001.803 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-051274 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,757.908 Underlying: Class A Common Stock · 8,001.803 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $4.4365 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 23:29 UTC | Mylan II B.V. MYL · Entity 16217 | PurchaseOrdinary Shares | 20,000 | $17.68 | $353,548.00 |
DisclosureSEC source: 0000899243-19-022077 · doc4.xml · nonDerivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,120 F1 · price: Represents the weighted average price of the reporting person's acquisition of 20,000 ordinary shares in transactions ranging from $17.65 to $17.70. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ordinary shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:16 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 10,729.938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-040238 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,756.105 Underlying: Class A Common Stock · 10,729.938 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $3.3085 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| March 29, 2019 Filed Apr 1, 2019 20:38 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 9,188.56 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021993 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,026.167 Underlying: Class A Common Stock · 9,188.56 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $3.8635 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 23:22 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 4,028 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006221 · doc4.xml · derivative · entry 5 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,028 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2019. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 2, 2019. Read SEC document |
| March 02, 2019 Filed Mar 5, 2019 23:22 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 4,028 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006221 · doc4.xml · nonDerivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:22 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 6,011 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006221 · doc4.xml · derivative · entry 4 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,011 Underlying: Ordinary Shares · 6,011 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2020. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2020. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:22 UTC | Mylan II B.V. MYL · Entity 16217 | GrantNon-Employee Director Stock Option-Right to Buy · Derivative | 4,352 | $0.00 Strike: $27.45 | $0.00 |
DisclosureSEC source: 0000899243-19-006221 · doc4.xml · derivative · entry 3 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 Underlying: Ordinary Shares · 4,352 shares Expires 2029-03-01 F1 · derivative.exercise_date: These options will vest in full on March 2, 2020 and expire on March 1, 2029. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 21:17 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 1,679.387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-000254 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,837.607 Underlying: Class A Common Stock · 1,679.387 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $4.4545 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:31 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 8,119.854 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-052767 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,158.22 Underlying: Class A Common Stock · 8,119.854 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $4.372 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:18 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 8,175.014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-041017 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,038.366 Underlying: Class A Common Stock · 8,175.014 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $4.3425 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 20:17 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 12,025.745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-022366 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,863.352 Underlying: Class A Common Stock · 12,025.745 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $2.952 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| March 03, 2018 Filed Mar 7, 2018 01:22 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 3,653 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006544 · doc4.xml · derivative · entry 5 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 3, 2018. F3 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. These RSUs vested in full on March 3, 2018. Read SEC document |
| March 03, 2018 Filed Mar 7, 2018 01:22 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 3,653 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006544 · doc4.xml · nonDerivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 01:22 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 4,028 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006544 · doc4.xml · derivative · entry 4 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,028 Underlying: Ordinary Shares · 4,028 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2019. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 2, 2019. Read SEC document |
| March 02, 2018 Filed Mar 7, 2018 01:22 UTC | Mylan II B.V. MYL · Entity 16217 | GrantNon-Employee Director Stock Option-Right to Buy · Derivative | 2,984 | $0.00 Strike: $40.97 | $0.00 |
DisclosureSEC source: 0000899243-18-006544 · doc4.xml · derivative · entry 3 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 Underlying: Ordinary Shares · 2,984 shares Expires 2028-03-02 F1 · derivative.exercise_date: These options will vest in full on March 2, 2019 and expire on March 2, 2028. Read SEC document |
| December 31, 2017 Filed Jan 2, 2018 21:18 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 2,872.062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-000189 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,837.607 Underlying: Class A Common Stock · 2,872.062 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $3.285 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| September 30, 2017 Filed Oct 2, 2017 20:13 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 9,162.13 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-054594 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,965.545 Underlying: Class A Common Stock · 9,162.13 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $3.7655 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:09 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 9,401.826 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-043255 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,803.415 Underlying: Class A Common Stock · 9,401.826 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $3.6695 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:08 UTC | GENWORTH FINANCIAL INC GNW · Entity 4085 | GrantDeferred Stock Units · Derivative | 8,563.982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-024680 · doc4.xml · derivative · entry 1 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,401.589 Underlying: Class A Common Stock · 8,563.982 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F2 · price: The number of Deferred Stock Units acquired represents a portion of the Reporting Person's annual retainer fee and was based on a price of $4.0285 per share of Class A Common Stock. F1 · derivative.exercise_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. F1 · derivative.expiration_date: Deferred Stock Units become payable in shares of Class A Common Stock beginning one year after termination of service as a director. The Reporting Person has previously elected to receive such amount in a single payment or in payments spread out for up to 10 years. Read SEC document |
| March 03, 2017 Filed Mar 8, 2017 00:27 UTC | Mylan II B.V. MYL · Entity 16217 | GrantRestricted Stock Units · Derivative | 3,653 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006755 · doc4.xml · derivative · entry 2 HIGGINS MELINA E · CIK 0001162304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,653 Underlying: Ordinary Shares · 3,653 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 3, 2018. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one ordinary share of Mylan N.V. These RSUs will vest in full on March 3, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.